FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2905627019> ?p ?o ?g. }

• W2905627019 endingPage "1003" @default.
• W2905627019 startingPage "993" @default.
• W2905627019 abstract "Mogamulizumab, a humanized defucosylated anti-C-C chemokine receptor 4 monoclonal antibody, has been approved in Japan for the treatment of C-C chemokine receptor 4-positive adult T-cell leukemia/lymphoma (ATL). This phase II study evaluated efficacy and safety of mogamulizumab in ATL patients with acute, lymphoma, and chronic subtypes with relapsed/refractory, aggressive disease in the US, Europe, and Latin America. With stratification by subtype, patients were randomized 2:1 to intravenous mogamulizumab 1.0 mg/kg once weekly for 4 weeks and biweekly thereafter (n=47) or investigator's choice of chemotherapy (n=24). The primary end point was confirmed overall response rate (cORR) confirmed on a subsequent assessment at 8 weeks by blinded independent review. ORR was 11% (95%CI: 4-23%) and 0% (95%CI: 0-14%) in the mogamulizumab and chemotherapy arms, respectively. Best response was 28% and 8% in the respective arms. The observed hazard ratio for progression-free survival was 0.71 (95%CI: 0.41-1.21) and, after post hoc adjustment for performance status imbalance, 0.57 (95%CI: 0.337-0.983). The most frequent treatment-related adverse (grade ≥3) events with mogamulizumab were infusion-related reaction and thrombocytopenia (each 9%). Relapsed/refractory ATL is an aggressive, poor prognosis disease with a high unmet need. Investigator's choice chemotherapy did not result in tumor response in this trial; however, mogamulizumab treatment resulted in 11% cORR, with a tolerable safety profile." @default.
• W2905627019 created "2019-01-01" @default.
• W2905627019 creator A5003883532 @default.
• W2905627019 creator A5008086243 @default.
• W2905627019 creator A5013717203 @default.
• W2905627019 creator A5035263938 @default.
• W2905627019 creator A5048486702 @default.
• W2905627019 creator A5048693285 @default.
• W2905627019 creator A5049384875 @default.
• W2905627019 creator A5050259782 @default.
• W2905627019 creator A5057128017 @default.
• W2905627019 creator A5058311223 @default.
• W2905627019 creator A5064856085 @default.
• W2905627019 creator A5064982710 @default.
• W2905627019 creator A5065307536 @default.
• W2905627019 creator A5069406522 @default.
• W2905627019 creator A5070164229 @default.
• W2905627019 creator A5080546745 @default.
• W2905627019 creator A5085028747 @default.
• W2905627019 creator A5091115060 @default.
• W2905627019 creator A5091650487 @default.
• W2905627019 date "2018-12-20" @default.
• W2905627019 modified "2023-10-07" @default.
• W2905627019 title "Mogamulizumab <i>versus</i> investigator’s choice of chemotherapy regimen in relapsed/refractory adult T-cell leukemia/lymphoma" @default.
• W2905627019 cites W134524789 @default.
• W2905627019 cites W1906100218 @default.
• W2905627019 cites W1909862186 @default.
• W2905627019 cites W1966822801 @default.
• W2905627019 cites W1982589145 @default.
• W2905627019 cites W1982817210 @default.
• W2905627019 cites W2006933182 @default.
• W2905627019 cites W2008383971 @default.
• W2905627019 cites W2009621572 @default.
• W2905627019 cites W2016534065 @default.
• W2905627019 cites W2028624655 @default.
• W2905627019 cites W2032176053 @default.
• W2905627019 cites W2048022927 @default.
• W2905627019 cites W2078089821 @default.
• W2905627019 cites W2080959198 @default.
• W2905627019 cites W2086143621 @default.
• W2905627019 cites W2092004631 @default.
• W2905627019 cites W2099464793 @default.
• W2905627019 cites W2109716912 @default.
• W2905627019 cites W2110220145 @default.
• W2905627019 cites W2110890034 @default.
• W2905627019 cites W2126772526 @default.
• W2905627019 cites W2134170049 @default.
• W2905627019 cites W2139891818 @default.
• W2905627019 cites W2146112074 @default.
• W2905627019 cites W2148895451 @default.
• W2905627019 cites W2158377087 @default.
• W2905627019 cites W2161984323 @default.
• W2905627019 cites W2166075265 @default.
• W2905627019 cites W2171301700 @default.
• W2905627019 cites W2294479069 @default.
• W2905627019 cites W2336865896 @default.
• W2905627019 cites W2416844197 @default.
• W2905627019 cites W2494933951 @default.
• W2905627019 cites W2519997684 @default.
• W2905627019 cites W2569436233 @default.
• W2905627019 cites W2583307538 @default.
• W2905627019 cites W2770343482 @default.
• W2905627019 cites W2885239461 @default.
• W2905627019 cites W4250268395 @default.
• W2905627019 cites W4297874890 @default.
• W2905627019 doi "https://doi.org/10.3324/haematol.2018.205096" @default.
• W2905627019 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6518882" @default.
• W2905627019 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30573506" @default.
• W2905627019 hasPublicationYear "2018" @default.
• W2905627019 type Work @default.
• W2905627019 sameAs 2905627019 @default.
• W2905627019 citedByCount "40" @default.
• W2905627019 countsByYear W29056270192019 @default.
• W2905627019 countsByYear W29056270192020 @default.
• W2905627019 countsByYear W29056270192021 @default.
• W2905627019 countsByYear W29056270192022 @default.
• W2905627019 countsByYear W29056270192023 @default.
• W2905627019 crossrefType "journal-article" @default.
• W2905627019 hasAuthorship W2905627019A5003883532 @default.
• W2905627019 hasAuthorship W2905627019A5008086243 @default.
• W2905627019 hasAuthorship W2905627019A5013717203 @default.
• W2905627019 hasAuthorship W2905627019A5035263938 @default.
• W2905627019 hasAuthorship W2905627019A5048486702 @default.
• W2905627019 hasAuthorship W2905627019A5048693285 @default.
• W2905627019 hasAuthorship W2905627019A5049384875 @default.
• W2905627019 hasAuthorship W2905627019A5050259782 @default.
• W2905627019 hasAuthorship W2905627019A5057128017 @default.
• W2905627019 hasAuthorship W2905627019A5058311223 @default.
• W2905627019 hasAuthorship W2905627019A5064856085 @default.
• W2905627019 hasAuthorship W2905627019A5064982710 @default.
• W2905627019 hasAuthorship W2905627019A5065307536 @default.
• W2905627019 hasAuthorship W2905627019A5069406522 @default.
• W2905627019 hasAuthorship W2905627019A5070164229 @default.
• W2905627019 hasAuthorship W2905627019A5080546745 @default.
• W2905627019 hasAuthorship W2905627019A5085028747 @default.
• W2905627019 hasAuthorship W2905627019A5091115060 @default.
• W2905627019 hasAuthorship W2905627019A5091650487 @default.
• W2905627019 hasBestOaLocation W29056270191 @default.

• next